[New aspects on "triple therapy" after coronary stent implantation]

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Antithrombotic/antiplatelet therapy is standard after coronary stent implantation.
• Optimal antithrombotic strategies for patients requiring oral anticoagulation post-stenting remain unclear.
• Current guidelines recommend antithrombotic therapy but lack specific guidance for this complex patient group.

Purpose of the Study:

• To review the risks and potential benefits of "triple therapy" in patients with coronary stents who also require oral anticoagulation.
• To discuss the clinical implications of combining oral anticoagulation with dual antiplatelet therapy (aspirin and clopidogrel).
• To inform clinical decision-making regarding antithrombotic management in this high-risk population.

Main Methods:

• Literature review and synthesis of existing evidence.
• Discussion of clinical trial data and observational studies.
• Analysis of bleeding risk and thrombotic events associated with triple therapy.

Main Results:

• Triple therapy (oral anticoagulation plus aspirin and clopidogrel) is frequently used but significantly elevates the risk of minor and major bleeding.
• Long-term use of triple therapy exacerbates bleeding complications.
• The balance between preventing stent thrombosis and managing bleeding risk is a critical challenge.

Conclusions:

• Triple therapy poses a substantial bleeding risk, particularly with prolonged use.
• Careful consideration of individual patient factors is crucial when deciding on antithrombotic regimens.
• Further research is needed to establish safer and more effective antithrombotic strategies for patients with coronary stents requiring oral anticoagulation.